These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10831634)

  • 1. Aminoglycosides and renal magnesium homeostasis in humans.
    von Vigier RO; Truttmann AC; Zindler-Schmocker K; Bettinelli A; Aebischer CC; Wermuth B; Bianchetti MG
    Nephrol Dial Transplant; 2000 Jun; 15(6):822-6. PubMed ID: 10831634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.
    Schaad UB; Wedgwood-Krucko J; Guenin K; Buehlmann U; Kraemer R
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):858-65. PubMed ID: 2512129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis.
    Schaad UB; Wedgwood-Krucko J; Suter S; Kraemer R
    J Pediatr; 1987 Oct; 111(4):599-605. PubMed ID: 3309236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients.
    Vic P; Ategbo S; Turck D; Husson MO; Tassin E; Loeuille GA; Deschildre A; Druon D; Elian JC; Arrouet-Lagandre C; Farriaux JP
    Eur J Pediatr; 1996 Nov; 155(11):948-53. PubMed ID: 8911895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of superinfections caused by pyocyanic bacillus in patients with mucoviscidosis. Efficacy of cefsulodin in combination with an aminoglycoside].
    Jehanne M
    Pathol Biol (Paris); 1989 May; 37(5):500-3. PubMed ID: 2780107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis.
    Akbar A; Rees JH; Nyamugunduru G; English MW; Spencer DA; Weller PH
    Acta Paediatr; 1999 Jul; 88(7):783-5. PubMed ID: 10447142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime.
    De Boeck K; Breysem L
    J Antimicrob Chemother; 1998 Mar; 41(3):407-9. PubMed ID: 9578170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.
    Vinks AA; Brimicombe RW; Heijerman HG; Bakker W
    J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Padoan R; Brienza A; Crossignani RM; Lodi G; Giunta A; Assael BM; Granata F; Passarella E; Vallaperta PA; Xerri L
    J Pediatr; 1983 Aug; 103(2):320-4. PubMed ID: 6348228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of cefepime in the treatment of bronchopulmonary disease exacerbation in pediatric patients with mucoviscidosis].
    Semykin SIu; Postnikov SS; Polikarpova SV; Dubovik LG; Kolbatova ES
    Antibiot Khimioter; 2005; 50(4):18-22. PubMed ID: 16392335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis.
    Schaad UB; Wedgwood J; Ruedeberg A; Kraemer R; Hampel B
    Pediatr Infect Dis J; 1997 Jan; 16(1):106-11; discussion 123-6. PubMed ID: 9002119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins.
    Zobell JT; Waters CD; Young DC; Stockmann C; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Feb; 48(2):107-22. PubMed ID: 22949297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.
    Mastella G; Agostini M; Barlocco G; Bonomi U; Borgo G; Bozzino L; Cabrini G; Cappelletti LM; Castellani L; Conforti M
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():297-311. PubMed ID: 6311788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cephalosporin therapeutics in cystic fibrosis.
    Blumer JL; Stern RC; Yamashita TS; Myers CM; Reed MD
    J Pediatr; 1986 May; 108(5 Pt 2):854-60. PubMed ID: 3517273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria.
    Scully BE; Neu HC
    Arch Intern Med; 1984 Jan; 144(1):57-62. PubMed ID: 6419690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Pseudomonas meningitis with ceftazidime with or without concurrent therapy.
    Rodriguez WJ; Khan WN; Cocchetto DM; Feris J; Puig JR; Akram S
    Pediatr Infect Dis J; 1990 Feb; 9(2):83-7. PubMed ID: 2179845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of the nephrotoxicity of amikacin in patients with cystic fibrosis].
    Hügli R; Artho G; Wiesmann UN; Peheim E; Schaad UB; Bianchetti MG
    Schweiz Med Wochenschr; 1992 Jun; 122(24):930-5. PubMed ID: 1377401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.